Abstract
Various tests exist to quantify beta cell (BC) function, but do not necessarily provide information on BC mass (BCM), while BCM seems an important predictor of future BC failure. A method for reliable BCM quantification would be a tremendous asset to better elucidate the pathophysiology of type 1 and type 2 diabetes (T1D and T2D), and to determine effects of therapeutic interventions.
Author information
Authors and Affiliations
Corresponding author
Additional information
1 Dept. of Nuclear Medicine, RUNMC, Nijmegen, The Netherlands, 2 Center for Radiopharmaceutical Sciences, Paul Scherrer institute, Villingen-PSI, Switzerland, 3 Dept. of Internal Medicine, RUNMC, Nijmegen, The Netherlands. Email: w.vanderweg@nucmed.umcn.nl
About this article
Cite this article
Woliner-van der Weg, W., Brom, M., Janssen, M. et al. PS18 - 2. Quantification of the beta cell mass based on 111In-Exendin imaging in patients with type 1 diabetes and healthy controls. NED. TIJDSCHR. DIABET. 11, 200–201 (2013). https://doi.org/10.1007/s12467-013-0161-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12467-013-0161-0